Kit for detecting 7 genetic markers of peripheral blood in early diagnosis of nasopharyngeal darcinoma

Abstract

The invention provides a kit for detecting 7 genetic markers of peripheral blood in early diagnosis of nasopharyngeal darcinoma. The kit comprises a peripheral blood total RNA extracting reagent, RT-PCR reaction liquid, time fluorescence quantitative RT-PCR reaction liquid and an SVM nasopharyngeal darcinoma diagnosis model, wherein the time fluorescence quantitative RT-PCR reaction liquid comprises primers of which the sequences are shown as SEQ IDNO:1-16; the primer sequences are SYBR Green fluorescence quantitative RT-PCR detection primers of the 7 genetic markers and reference gene GAPD; and the 7 genetic markers are HERC5, DLG7, PPARG, PLK1, KIF15, KLHL25 and MYST4. The invention also provides a using method for the kit. The kit has the advantages of high sensitivity, specificity and convenience, and can be used as aided diagnosis and early diagnosis technology for the nasopharyngeal darcinoma.

Description

technical field [0001] The invention relates to the field of molecular biology, in particular to a detection kit for seven gene markers in peripheral blood used for early diagnosis of nasopharyngeal carcinoma. Background technique [0002] Nasopharyngeal carcinoma (NPC) is a common malignant tumor in southern my country and Southeast Asia. It develops progressively and often metastasizes and spreads later. At present, nasopharyngeal carcinoma mainly relies on radiotherapy, and the prognosis of patients with advanced tumors is still very poor. The 5-year survival rate of stage I patients after radiotherapy can reach 90%, and the 5-year survival rate of stage IV patients is only 30%. Therefore, early detection is the key to improving the cure rate. key to rate. Serological screening for high-risk groups of nasopharyngeal carcinoma is an important way to detect early nasopharyngeal carcinoma. Because changes in serological indicators usually precede the appearance of clinical...

AI Technical Summary

Problems solved by technology

Currently commonly used serological indicators are VCA-IgA and EA-IgA. Clinical laboratories often use indirect enzyme staining to measure serum VCA-IgA and EA-IgA antibody titers for auxiliary diagnosis of nasopharyngeal carcinoma, but there are still some patients All EBV serological indicators are negative, and such patients cannot be screened out by EBV serology

At the same time, the false positive of VCA-IgA will also cause psychological pressure to Epstein-Barr virus carriers

Images